Antibody-Drug Conjugate SC16LD6.5
Semantic Scholar uses AI to extract papers important to this topic.
DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with… Expand The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade… Expand Expression of DLL3 was examined in additional tumor types, as it was found to be highly expressed in tumor-initiating cells (TIC… Expand LBA8505Background: SCLC remains among the most deadly of malignancies. Rovalpituzumab tesirine is a first-in-class ADC comprised… Expand ABSTRACT Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug… Expand Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers… Expand An in situ study of the kinetics of relaxation of the gamma-gamma' lattice mismatch in the single-crystal Ni-base superalloy SC16… Expand Thermodynamic equilibrium and Gulliver – Scheil as well as diffusion calculations using the DICTRA program have been made to… Expand A first-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs is reported. For both… Expand